Isthmus Partners’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Isthmus Partners’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-176,170	Closed	-$264K	–	273
2018 Q1	$264K	Buy	176,170 +11,595	+7%	+$20.2K	0.07%	120
2017 Q4	$234K	Buy	164,575 +4,084	+3%	+$6.7K	0.06%	123
2017 Q3	$368K	Buy	160,491 +6,104	+4%	+$8.17K	0.1%	114
2017 Q2	$208K	Buy	154,387 +1,285	+0.8%	+$1.86K	0.06%	126
2017 Q1	$328K	Buy	153,102 +7,110	+5%	+$26.7K	0.1%	118
2016 Q4	$644K	Buy	145,992 +8,443	+6%	+$40.1K	0.19%	95
2016 Q3	$681K	Buy	137,549 +28,054	+26%	+$128K	0.22%	80
2016 Q2	$361K	Buy	109,495 +62,053	+131%	+$234K	0.12%	110
2016 Q1	$168K	Buy	+47,442	New	+$245K	0.06%	130

Other funds holding ARLZ

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Salzhauer Michael $292M AUM 30% 1-Year Est. Return

PCM

PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

SCP

Silverleafe Capital Partners Germantown, Tennessee $367M AUM 37.49% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Isthmus Partners's ARLZ Position: Q2 2018 in Review

Isthmus Partners sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2018, closing a stake of 176,170 shares — an estimated $264K sold.

Isthmus Partners first reported a position in ARLZ in Q1 2016 and held it in 9 quarters. The position peaked at $681K in Q3 2016. 48 funds tracked by Wall St. Rank hold ARLZ as of Q2 2018.

Isthmus Partners reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
Isthmus Partners sold 176,170 Aralez Pharmaceuticals Inc. shares in Q2 2018, an estimated $264K.
Isthmus Partners first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 9 quarters.
Isthmus Partners's Aralez Pharmaceuticals Inc. position peaked at $681K in Q3 2016.
48 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2018.

Based on Isthmus Partners's 13F filing for Q2 2018, filed 2 Aug 2018.